Antares Pharma & Eli Lilly and Company File Joint Patent Application; Needle Free Injection Device for Diabetes and Obesity Treatment.EXTON, Pa. -- Antares Pharma, Inc. (Amex:AIS) announced today that Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. (Lilly) has filed a provisional patent application with Antares for a needle-free injection device that is the result of joint development work done under the September 2003 agreement with Lilly. This agreement provides for development of needle-free injection devices in the fields of diabetes and obesity. The filing incorporates development work focused on making products more patient friendly related to the Antares' core needle-free injector technology. This work could enhance the needle-free technology that Antares already sells into the U.S. insulin market as the MediJector VISION(R). The intellectual property sought is the result of user and engineering studies focused on helping diabetics with their daily insulin requirements and eliminating needles from their lives. In addition to needle-free injections' obvious advantages, the completed work has made other aspects of the injection even more user friendly. The development work that has been completed, and for which broad patent protection is sought, is in the area of "ease of use". Peter Sadowski, Ph.D., Vice President and General Manager of the Device Division of Antares Pharma stated, "It is our belief that the results of the work to date have included features that could make this one of the easiest to use reusable needle-free injectors, and ease of use is what patients are looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. ." Jack E. Stover stover stalks of maize plants from which mature corn cobs have been harvested as grain, or grain sorghum plants from which heads have also been removed. The stover is usually fed by turning the cattle into the field and is subject to fungal infection, sometimes causing mycotoxicosis. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , of Antares commented further, "I am pleased to report that the joint development process with Lilly has yielded some important intellectual property that both companies have sought to protect. We are confident that recent approvals of alternative insulin delivery systems will provide a broader awareness that our MediJector VISION(R) and its next generation products are available as simple and reliable alternatives to traditional needle and syringe self injections." About Antares Pharma Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. device engineering capabilities. Antares' current technology platforms include its ATD ATD Anthropomorphic Test Dummy ATD Attention to Detail ATD Advanced Technology Demonstration AtD Achieving the Dream ATD Atmospheric Technology Division (US National Center for Atmospheric Research) ATD Assistant Technical Director (TM) Advanced Transdermal Delivery system transdermal delivery system: see skin patch. , and its related TecTix(TM) system for topical and transmucosal delivery, its Easy Tec(TM) oral fast-melt technology, and subcutaneous injection Noun 1. subcutaneous injection - an injection under the skin injection, shot - the act of putting a liquid into the body by means of a syringe; "the nurse gave him a flu shot" technology platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM)/Vision(R) reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland. Statements included in this press release that are not historical in nature, including those, relating to Antares' product pipelines' ability to address unmet medical needs, if approved are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion